Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12130583 | 0.87 | SLC6A4 (0.50) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL12130507 | 0.87 | HRH3 (0.52) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL994382 | 0.85 | SLC6A2 (0.45) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL12130610 | 0.85 | SLC6A3 (0.45) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL12130553 | 0.85 | SLC6A2 (0.42) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12130449 | 0.84 | HRH3 (0.43) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL12130554 | 0.84 | HRH3 (0.43) | HRH3SLC6A4TSHRSLC6A2SLC6A3 | |
| SCHEMBL12130459 | 0.83 | HRH3 (0.43) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12130611 | 0.83 | LTA4H (0.47) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12130604 | 0.83 | HRH3 (0.46) | HRH3SLC6A2SLC6A3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| WO-2011008666-A2 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A4 1647/4885SIGMAR1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.